Important products aren’t always good or bad. Often, they fall somewhere in-between, all the while offering perspective on where a particular industry has found itself … and where it might be going.
Julie Hanson is managing editor of the Northeast region for CBSNews.com. She previously worked at CBS Boston for more than 20 years. Her prior experience includes WBBM in Chicago, WCAU in Philadelphia ...
Journalists Josh Dawsey, Tyler Pager and Isaac Arnsdorf are out with a new book unpacking the twists and turns of the 2024 presidential election. Drawing on hundreds of interviews with insiders, the ...
We're now more than 18 months and nearly 19,000 miles into ownership of our 2024 BMW iX xDrive50, and it's been a good year and a half. When we bought it, we intentionally got a machine with as few ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A legal case questioning the accuracy of the 2024 election is moving ...
May 29 (UPI) --AMC is previewing Nautilus, its upcoming adventure drama based on the 1869 novel Twenty Thousand Leagues Under the Sea by Jules Verne, and starring Shazad Latif as Captain Nemo. Nemo is ...
Renewable energy – solar, wind, geothermal, hydropower, biomass – accounted for more than 90% of total US electrical generating capacity added in 2024, according to data released yesterday by the ...
Health care and government were the two sectors that saw the most job growth in both 2024 and 2023. But a second Trump administration may pose risks to growth in both areas. Conversely, Trump's ...
Analysts project 2024 sales to near 16 million vehicles GM maintains sales crown with 2.7 million vehicles sold Stellantis and Tesla face challenges DETROIT, Jan 3 (Reuters) - U.S. new-car sales in ...
The New York Times may feature all the news that’s fit to print, but it also has all the games that are fun to play, with the numbers for 2024 to prove it. Known for its iconic crossword puzzle that ...
Comparing the FDA new drug approval lists from 2023 and 2024 reveals a significant difference in the size of the companies that achieved the regulatory triumphs. In 2023, among the 68 FDA approvals ...
The FDA’s Center for Drug Evaluation and Research (CDER) approved 50 new small molecules, biologics and oligonucleotide therapeutics last year. The class of 2024 was a little smaller than that of 2023 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results